Ioanna Savvidou

Melbourne, VIC 3004, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Endothelial -targeted CD39 is protective in a mouse model of global forebrain ischaemia.

Endothelial -targeted CD39 is protective in a mouse model of global forebrain ischaemia.

Journal: Journal of neuroinflammation

Published: August 01, 2024

Development of endothelial-targeted CD39 as a therapy for ischemic stroke.

Development of endothelial-targeted CD39 as a therapy for ischemic stroke.

Journal: Journal of thrombosis and haemostasis : JTH

Published: December 21, 2023

Combination of Histone Deacetylase Inhibitor Panobinostat (LBH589) with β-Catenin Inhibitor Tegavivint (BC2059) Exerts Significant Anti-Myeloma Activity Both In Vitro and In Vivo.

Combination of Histone Deacetylase Inhibitor Panobinostat (LBH589) with β-Catenin Inhibitor Tegavivint (BC2059) Exerts Significant Anti-Myeloma Activity Both In Vitro and In Vivo.

Journal: Cancers

Published: January 11, 2022

Correction: Liquid biopsy: an evolving paradigm for the biological characterisation of plasma cell disorders.

Correction: Liquid biopsy: an evolving paradigm for the biological characterisation of plasma cell disorders.

Journal: Leukemia

Published: September 21, 2021

Liquid biopsy: an evolving paradigm for the biological characterisation of plasma cell disorders.

Liquid biopsy: an evolving paradigm for the biological characterisation of plasma cell disorders.

Journal: Leukemia

Published: February 03, 2021

Human myeloma cell- and plasma-derived extracellular vesicles contribute to functional regulation of stromal cells.

Human myeloma cell- and plasma-derived extracellular vesicles contribute to functional regulation of stromal cells.

Journal: Proteomics

Published: November 27, 2020

TOP2A expression predicts responsiveness to carfilzomib in myeloma and informs novel combinatorial strategies for enhanced proteasome inhibitor cell killing.

TOP2A expression predicts responsiveness to carfilzomib in myeloma and informs novel combinatorial strategies for enhanced proteasome inhibitor cell killing.

Journal: Leukemia & lymphoma

Published: November 02, 2020

Phase II trial of single-agent panobinostat consolidation improves responses after sub-optimal transplant outcomes in multiple myeloma.

Phase II trial of single-agent panobinostat consolidation improves responses after sub-optimal transplant outcomes in multiple myeloma.

Journal: British journal of haematology

Published: July 06, 2020

Monitoring tumour burden and therapeutic response through analysis of circulating tumour DNA and extracellular RNA in multiple myeloma patients.

Monitoring tumour burden and therapeutic response through analysis of circulating tumour DNA and extracellular RNA in multiple myeloma patients.

Journal: Leukemia

Published: October 29, 2018

β-Catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma.

β-Catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma.

Journal: Molecular cancer therapeutics

Published: September 30, 2016

Showing 1-10 of 10

Last Updated: 09/26/2026